Novartis: wins EU approval for multiple sclerosis treatment
(CercleFinance.com) - Swiss drugmaker Novartis said that it has won approval from European authorities for a treatment of adult patients with secondary progressive multiple sclerosis with active disease.
The company said the that the European Commission has approved Mayzent for the treatment of adult patients with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
These patients did not have, until now, an oral treatment that has been shown to be effective in delaying progression in this patient population, the group said.
The company said that it is working to ensure that European patients can start benefitting from this treatment "as quickly as possible." It is estimated that up to 80% of relapsing remitting multiple sclerosis
It is estimated that up to 80% of relapsing remitting multiple sclerosis patients will eventually transition to secondary progressive multiple sclerosis.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The company said the that the European Commission has approved Mayzent for the treatment of adult patients with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
These patients did not have, until now, an oral treatment that has been shown to be effective in delaying progression in this patient population, the group said.
The company said that it is working to ensure that European patients can start benefitting from this treatment "as quickly as possible." It is estimated that up to 80% of relapsing remitting multiple sclerosis
It is estimated that up to 80% of relapsing remitting multiple sclerosis patients will eventually transition to secondary progressive multiple sclerosis.
Copyright (c) 2020 CercleFinance.com. All rights reserved.